BioSante pancreatic cancer vaccine extends survival in early stage trial

BioSante Pharmaceuticals, Inc. announced on 27 February 2012 that results from a Phase Ib clinical study that show its GVAX Pancreas cancer vaccine increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma (PDA), … Continue reading

Angiochem signs collaboration with GSK for lysosomal storage diseases

Montreal-based Angiochem announced on 27 February 2012 that they have signed a deal with GlaxoSmithKline, under which they will discover, develop and commercialize treatments for lysosomal storage diseases (LSDs).  The deal includes an upfront payment of $31.5M, and could be worth up … Continue reading

Positive phase 3 results for vedolizumab in ulcerative colitis

Takeda announced on 20 February 2012, that the GEMINI 1 phase 3 trial, evaluating vedolizumab (MLN0002) in moderately to severely active ulcerative colitis, met its primary endpoints vs. placebo after 6 weeks induction therapy and 1 year of follow-up treatment.  The 895 patients included … Continue reading

Cancer Research UK calls for improvement of the EU clinical trials directive

In an article published in The Telegraph on 14 February 2012 Professor Peter Johnson, chief clinician at Cancer Research UK, said that while the principles of the EU clinical trials directive were “sensible” the increased bureaucracy which has arisen from its … Continue reading

MSD inform US doctors of interactions between Victrelis and HIV med.s

On 8 February 2012, Merck sent out a “dear doctor” letter to inform US physicians of drug interactions observed between boceprevir (Victrelis) and commonly-used HIV drugs.  Concomitant administration of boceprevir with ritonavir (Norvir) in combination with atazanavir (Reyataz) or darunavir (Prezista),or with … Continue reading